产品编号：GM-87970MAB
产品名称：Anti-GDF8 hIgG4 Reference Antibody (Apitbio)
目录价：询价
产品编号：GM-87970MAB
产品名称：Anti-GDF8 hIgG4 Reference Antibody (Apitbio)
目录价：询价
GM-87970MAB-1mg / 1 mg
GM-87970MAB-5mg / 5 mg
GM-87970MAB-25mg / 25 mg
GM-87970MAB-50mg / 50mg
GM-87970MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target GDF8
Clone Apitegromab
Alternative Names MSTN, MSLHP
Source/Isotype Monoclonal human IgG4, lambda
Application /
Description GDF8 (Growth Differentiation Factor 8), also known as Myostatin, is a secreted protein that belongs to the Transforming Growth Factor-β (TGF-β) superfamily. Apitegromab is a monoclonal antibody drug that targets a specific region of the GDF8 precursor. It works by binding to the immature GDF8 precursor or associated activator proteins, thereby inhibiting the activity of Myostatin and improving muscle function.Compared to other therapies that directly antagonize mature GDF8 protein, Apitegromab may offer greater selectivity and safety by avoiding the complete inhibition of other proteins in the TGF-β family, thus reducing the risk of potential side effects.
Formulation phosphate-buffered solution, pH 7.4.
产品编号：GM-87970MAB
产品名称：Anti-GDF8 hIgG4 Reference Antibody (Apitbio)
目录价：询价
GM-87970MAB-1mg / 1 mg
GM-87970MAB-5mg / 5 mg
GM-87970MAB-25mg / 25 mg
GM-87970MAB-50mg / 50mg
GM-87970MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target GDF8
Clone Apitegromab
Alternative Names MSTN, MSLHP
Source/Isotype Monoclonal human IgG4, lambda
Application /
Description GDF8 (Growth Differentiation Factor 8), also known as Myostatin, is a secreted protein that belongs to the Transforming Growth Factor-β (TGF-β) superfamily. Apitegromab is a monoclonal antibody drug that targets a specific region of the GDF8 precursor. It works by binding to the immature GDF8 precursor or associated activator proteins, thereby inhibiting the activity of Myostatin and improving muscle function.Compared to other therapies that directly antagonize mature GDF8 protein, Apitegromab may offer greater selectivity and safety by avoiding the complete inhibition of other proteins in the TGF-β family, thus reducing the risk of potential side effects.
Formulation phosphate-buffered solution, pH 7.4.
